Holen Sie sich die Stockscreener-App
0.5215
6.71%
-0.0375
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Lexaria Bioscience Corp (LEXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexaria Bioscience Corp (LEXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LEXX|Lexaria Bioscience Corp|Price:0.559|Chg%:-0.011 - TradingKey
Enterprise value to revenue forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Cash Flow - TradingKey
Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) Institutional Confidence - TradingKey
Price to book forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp. 10-Q Q3 2026: Financial Results, NASDAQ Listing, and Key Highlights - Minichart
Lexaria Bioscience narrows Q3 loss to $(0.08) per share - scanx.trade
LEXARIA BIOSCIENCE ($LEXX) Releases Q3 2026 Earnings - Quiver Quantitative
Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary - TradingView
Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid - Stock Titan
Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026 - marketscreener.com
Lexaria Bioscience Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Lexaria reports pharmaceutical partnership discussions at BIO - Investing.com
Lexaria reports pharmaceutical partnership discussions at BIO By Investing.com - Investing.com Nigeria
Lexaria Updates Business Development - Investing News Network
Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows - Stock Titan
LEXXLexaria Bioscience Corp Forecast, Target Price - Finviz
Lexaria Bioscience Corp. Actuals & Estimates (NASDAQ:LEXX) - TradingView
Lexaria Begins Dosing in Human Study Evaluating Oral Semaglutide Formulations Against Wegovy - citybuzz -
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule - Investing News Network
Lexaria starts 5-week human GLP-1 study using tablet and capsule forms - Stock Titan
Lexaria begins GLP-1 study dosing evaluating DehydraTECH-semaglutide - scanx.trade
Lexaria Bioscience (LEXX) Advances in Animal Study #1 on Formula - GuruFocus
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule - Investing News Network
Lexaria starts animal GLP-1 study, adds Australian patent - Stock Titan
Lexaria begins dosing in GLP-1 study, receives patent - scanx.trade
Lexaria Bioscience Corp (LEXXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexaria Bioscience Corp (LEXXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Corp. Financial Disclosures & SEC Filings - TradingView
Lexaria Bioscience Corp (LEXXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexaria Bioscience Corp (LEXXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexaria Bioscience Corp (LEXXW) Institutional Confidence - TradingKey
Lexaria Bioscience Corp (LEXX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexaria Bioscience Corp (LEXXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Corp (LEXX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexaria Bioscience Corp (LEXX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexaria Bioscience (LEXX) Advances Drug Delivery Technology - GuruFocus
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand - Investing News Network
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand - Investing News Network
Lexaria says GLP-1 drugs are moving into more diseases and markets - Stock Titan
Lexaria Bioscience Corp (LEXXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lexaria Bioscience Corp (LEXXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXXW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LEXX: Animal & Human GLP-1 Studies Continue - Yahoo Finance
Lexaria Bioscience (LEXX) Completes Dosing in Key Animal Study - GuruFocus
Lexaria completes dosing study on next-generation GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria completes dosing study on next-generation GLP-1 drugs - Investing.com
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):